Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 20.32 yuan on November 21, 2025, down 3.79% from the previous day, indicating a negative trend in recent trading activity [1]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, a year-on-year increase of 3.28% [3]. - The net profit attributable to shareholders was 208 million yuan, a year-on-year decrease of 19.25% [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, up 5.89% year-on-year [3]. - The company’s gross profit margin stands at 39.34%, which is lower than the industry average of 51.22% [3]. Market Position and Valuation - Meihao Medical has a total market capitalization of 11.559 billion yuan, ranking 26th in the medical device industry [3]. - The company’s price-to-earnings ratio (P/E) is 41.64, which is lower than the industry average of 54.54, ranking 49th [3]. - The price-to-book ratio (P/B) is 3.12, compared to the industry average of 3.77, ranking 78th [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd [3]. Recent Trading Activity - On November 21, 2025, the net outflow of main funds was 5.339 million yuan, accounting for 6.37% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2]. - The average target price set by 14 institutions over the past 90 days is 25.2 yuan, with 12 buy ratings and 2 hold ratings [4].
股票行情快报：美好医疗（301363）11月21日主力资金净卖出533.90万元